Attovia Therapeutics
Creating medicines for immune-mediated disease using ATTOBODY®, a proprietary biologics platform for complex biologics.
53 employees · est. 2023 · San Carlos, United States
OncoResponse is the older company (2023 vs 2016); Attovia Therapeutics is the larger of the two.
Side-by-Side Comparison
| Metric | Attovia Therapeutics | OncoResponse |
|---|---|---|
| Founded | ||
| Founded | 2023 | 2016 older |
| Headquarters | ||
| Headquarters | San Carlos, United States | Houston, United States |
| Employees | ||
| Employees | 53 larger | 10 |
| Industry | ||
| Industry | Biotechnology, Health Care, Health and Wellness | Biopharma, Biotechnology, Health Care |
| Funding Stage | ||
| Funding Stage | Series C | Unknown |
| Total Funding | ||
| Total Funding | $255.00M | $117.10M |
| Funding Rounds | ||
| Funding Rounds | 3 | 6 |
| Services | ||
| Services | Development of multispecific medicines, Advanced protein design using ATTOBODY™ platform, Preclinical and clinical development, Strategic partnerships and collaborations | Development of novel cancer immunotherapies, Discovery of human antibodies, Partnering with collaborators in immuno-oncology, Preclinical studies |
| Target Customers | ||
| Target Customers | Patients with high unmet need in immune-mediated diseases, Healthcare providers in need of advanced biologic therapies, Academic and research institutions involved in immunology, Pharmaceutical companies seeking collaborative drug development | Biopharmaceutical companies, Oncology researchers, Cancer patients, Clinical study collaborators |
| Taxonomy | ||
| Taxonomy | Biotherapeutics Development, Immune-mediated Diseases, Multispecific Biologics, ATTOBODY Platform, Biparatopic Target Engagement, High Affinity Therapeutics, Biologic Engineering, Immune System Modulation, Evolution-based Discovery, Oncology Therapeutics, Nanobody Technology, Cancer Treatment Advancement, Rapid Tissue Penetration, Selective Binding Agents, Therapeutics Pipeline Innovation | Immuno-oncology, Biotech, Cancer Immunotherapy, Antibody Platform, B-cell Discovery, Tumor Microenvironment, Monoclonal Antibodies, Immune Activation, TME Immunosuppression, Elite Cancer Responders, Novel Therapeutics, Myeloid Biology, Clinical Trials, Human Antibodies |
| Website | ||
| Website | attovia.com | oncoresponse.com |
About Attovia Therapeutics
Attovia Therapeutics, founded in 2023 and headquartered in the United States, is advancing the biotechnology landscape with its proprietary ATTOBODY® platform. This innovative solution focuses on developing biotherapeutics targeting immune-mediated diseases. The platform's unique spatial positioning...
About OncoResponse
OncoResponse, founded in 2016, is an innovative player in the immuno-oncology biotech sector. This biopharma company is particularly notable for its strategic collaboration with the MD Anderson Cancer Center, which amplifies its capabilities in treating cancer. Utilizing a proprietary B-cell discov...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at Attovia Therapeutics and OncoResponse — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at Attovia Therapeutics and OncoResponse — by email.
Frequently Asked Questions
Compare Attovia Therapeutics with someone else
Start typing a company name or domain.